Compare Expensify Inc (EXFY) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs IDEXX Laboratories, Inc. — how do they compare? Expensify Inc trades at $1.78 (market cap $170.21M), while IDEXX Laboratories, Inc. trades at $572.36 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 258.2× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| EXFY | IDXX | |
|---|---|---|
Market Cap | $170.21M | $43.94B |
Sector | Technology | Health |
52-Week High | $2.33 | $766.68 |
52-Week Low | $0.75 | $514.61 |
Enterprise Value | $109.24M | $44.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $1.755, down 3.04% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative profitability metrics with a -14.68% net income margin. Recent developments include AI-powered expense management expansions and a $25 million stock repurchase program, indicating strategic initiatives to drive growth.
The outlook remains cautious due to persistent unprofitability despite revenue stabilization around $140 million. Investment opportunities lie in operational efficiency gains and new product integrations, but risks include competitive pressure and the challenge of achieving sustainable profitability. Analyst sentiment is divided with equal buy/hold ratings, reflecting uncertainty about the company's turnaround potential.
IDXX stock trades at $540.68, down 4.15% in the last session, with technical indicators showing a bearish bias. Fundamentally, the company demonstrates strong profitability with a 24.63% net margin and consistent earnings beats in recent quarters. Revenue growth continues, reaching $4.3B in 2025. Analyst sentiment remains predominantly positive with a 59% buy rating, though technical signals conflict with this fundamental strength.
The outlook balances robust fundamentals against technical weakness. Investment opportunity lies in sustained high profitability and market leadership in veterinary diagnostics, but risks include elevated valuation multiples (P/E 40.99) and bearish technical momentum that may pressure the stock near-term despite positive analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
